(MedPage Today) — Building on bispecific antibodies, four of which have been approved by the FDA to treat relapsed/refractory multiple myeloma, next-generation trispecific antibodies are yielding high response rates in heavily pretreated disease…
Source link : https://www.medpagetoday.com/spotlight/asco-mm/116833
Author :
Publish date : 2025-08-05 16:23:00
Copyright for syndicated content belongs to the linked Source.
